Motility News

SAN DIEGO — Over the next four days, the gastroenterology community will convene in the San Diego Convention Center for Digestive Disease Week 2019, the specialty’s largest scientific conference.

Healio Gastroenterology and Liver Disease compiled a list of some of the top stories we posted in April.

VIENNA — Lubiprostone was tolerable and improved hepatic markers among patients with nonalcoholic fatty liver disease, according to data presented at the International Liver Congress 2019.

Mood likely has an impact on a person’s specific bowel habits, according to study results.

Motegrity, a once-daily, oral selective serotonin-4 receptor agonist, is now available via prescription in the U.S. for adults with chronic idiopathic constipation, according to a company press release.

The FDA has approved the reintroduction of Zelnorm, a twice-daily oral treatment for irritable bowel syndrome with constipation in women aged under 65 years, according to a company press release.

Children delivered by cesarean were more likely to have milk allergy and GERD, according to findings presented at the American Academy of Allergy, Asthma and Immunology.

Researchers from Rutgers University found that most patients who overdosed on Imodium did so because they were misusing it or abusing it as an opioid substitute, according to study results published in Clinical Toxicology.

The American Gastroenterological Association has named the 2019 winners of its annual Recognition Awards, bestowed on leaders in gastroenterology to honor their contribution and achievements in the specialty.

Recurrent abdominal pain, or RAP, encompasses a group of functional gastrointestinal disorders commonly experienced by children. Currently, no consensus exists about what the gold standard treatment is for these conditions.